Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05113459
Other study ID # RC48-C018
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date December 18, 2021
Est. completion date June 18, 2024

Study information

Verified date November 2021
Source Nanfang Hospital of Southern Medical University
Contact liying zhao, PhD
Phone 13430396746
Email gzliguoxin@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is a multi-center, open, single-arm, superior phase II clinical study.


Description:

The study included 40 patients with gastric cancer or gastroesophageal junction adenocarcinoma with clinical stage T3-4aN+M0; and confirmed after HER2 IHC results Patients with medium and high expression of HER2 (defined as: IHC 2+ 3+); the neoadjuvant treatment plan is: disitamab vedotin + PD-1 + capecitabine; the main goal of the study is to explore The effectiveness of disitamab vedotin combined with PD-1 monoclonal antibody and capecitabine in the neoadjuvant treatment of locally advanced gastric or gastroesophageal junction adenocarcinoma, and ultimately provide a basis for the update of treatment decisions for locally advanced gastric or gastroesophageal junction adenocarcinoma Proof of medical evidence.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date June 18, 2024
Est. primary completion date December 18, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Sign the informed consent form; 2. Age 18-75 years old (including 18 years old and 75 years old); 3. Expected survival period = 12 weeks; 4. ECOG physical fitness score 0 or 1 point; 5. Patients with gastric cancer or gastroesophageal junction adenocarcinoma (Siewert type I-III) confirmed by histology and/or cytology, clinical stage T3-4aN+M0 (determined by the 8th edition of the AJCC staging system); 6. Use pre-treatment endoscopic biopsy samples for HER2 detection in the local laboratory: HER2 high expression confirmed after IHC results (defined as: IHC 2+ 3+); 7. Sufficient organ function: Bone marrow function: hemoglobin =9g/dL; absolute neutrophil count =1.5×10 9/L; white blood cell count =3.0×10 9/L; platelet =100×10 9/L; Liver function: serum total bilirubin =1.5 times the upper limit of normal (ULN); when there is no liver metastasis, alanine aminotransferase (ALT), aspartate aminotransferase (AST and alkaline phosphatase (ALP) =2.5 × ULN; Renal function: blood creatinine = 1.5×ULN, or creatinine clearance rate (CrCl) = 60 mL/min calculated by Cockcroft-Gault formula method; Heart function: NYHA classification <3; left ventricular ejection fraction =50%; 8. For female subjects: women of childbearing age agree to use a medically approved contraceptive method (such as intrauterine device, contraceptives, or contraceptives) during the study treatment period and within 6 months after the end of the study treatment period for the test group participants Set), the blood pregnancy test must be negative within 7 days before the study administration (surgical sterilization or subjects aged =60 years can choose not to have a blood pregnancy test), and must be non-lactating; for male subjects: should For surgical sterilization, or agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period of the experimental group subjects; 9. Must voluntarily join this study and sign an informed consent form. Exclusion Criteria: 1. Stage IV (metastatic) or unresectable gastric cancer or gastroesophageal junction adenocarcinoma (GEJ) as determined by the investigator; 2. Past systemic treatment for gastric cancer; 3. There is a history of malignant tumors in the 5 years before screening (except for gastric cancer), except for malignant tumors with negligible risk of metastasis or death (for example, 5-year OS rate> 90%), such as cervical carcinoma in situ after appropriate treatment , Non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ or stage I uterine cancer; 4. Severe cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage and cerebral infarction (except for lacunar infarcts that are asymptomatic and do not require treatment); 5. There are other lung diseases that require treatment or are serious, including but not limited to active tuberculosis, interstitial lung disease, etc.; 6. Are suffering from an active infection that requires systemic treatment; 7. There are active autoimmune diseases that require systemic treatment in the past 2 years (such as corticosteroids or immunosuppressive drugs, etc.), and related alternative treatments (such as thyroxine, insulin, or the physiological effects of adrenal or pituitary insufficiency) are allowed Corticosteroid replacement therapy); 8. Major surgery other than diagnosis was received within 4 weeks before the start of study treatment, or major surgery is expected to be required during the study period 9. Serious infections that occurred within 4 weeks before the start of the study treatment, including but not limited to hospitalization due to complications of infection, bacteremia, or severe pneumonia 10. Treat with therapeutic antibiotics within 2 weeks (intravenous antibiotics) or 5 days (oral antibiotics) before starting the study treatment - Patients who receive prophylactic antibiotics (for example, to prevent urinary tract infections or prevent exacerbations of chronic obstructive pulmonary disease) are eligible to participate in the study. 11. Have previously received allogeneic stem cell or solid organ transplantation; 12. Any other diseases, metabolic dysfunction, physical examination results or clinical laboratory results that lead to the prohibition of the use of experimental drugs, affect the interpretation of the results, put the patient at a high risk of treatment complications; 13. All treatments using live attenuated vaccines within 4 weeks before the start of the study treatment, or expected to be vaccinated during PD-1 treatment or within 5 months after the last PD-1 administration; 14. Have a clear history or current history of neurological or mental disorders, including epilepsy or dementia; 15. HIV test results are positive; patients with active hepatitis B or C (HBsAg positive and HBV DNA titers higher than the upper limit of normal when HBsAg is positive; HCVAb positive and HCV RNA titers higher than the upper limit of normal when HBsAg is positive); 16. There are factors that significantly affect the absorption of oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction; 17. In patients who choose to receive capecitabine, it is required to use the antiviral drug solivudine (antiviral drug) or chemical structure analogs, such as brivudine. These drugs are not allowed to be used within 4 weeks before the start of study treatment including capecitabine; 18. Known to have hypersensitivity or delayed allergic reactions to certain components of RC48-ADC or similar drugs; 19. Those who are allergic to PD-1; 20. It is estimated that the compliance of the patient to participate in this clinical study is sufficient or the researcher thinks that there are other subjects who are not suitable to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
disitamab vedotin:2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Guoxin Li

Outcome

Type Measure Description Time frame Safety issue
Primary pathologic Complete Response, PCR After completion of neoadjuvant systemic therapy (NAST), hematoxylin and eosin (H&E) assessments were performed on the completely resected gastric cancer or gastroesophageal junction adenocarcinoma sample and all sampled regional lymph nodes. No evidence of residual active tumor cells was found (currently YpT0N0 in the 8th edition of the AJCC staging system) 3 months-6 months
Secondary Major pathologic response, MPR Less than 10% of tumor cells were found in pathological resection specimens. 3 months-6 months
Secondary R0 resection rate No residue under the microscope after tumor resection 3 months -6 months
Secondary Objective response rate, ORR Refers to the proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time after neoadjuvant treatment (mainly for solid tumors). It includes complete remission (CR, Complete Response) and partial remission (PR, Partial Response) cases 3 months-6 months
Secondary Relapse-free survival time , RFS The time from the start of randomization to the recurrence of the disease or the death of the patient due to disease progression. 1-5 years
Secondary Overall survival , OS The time from the start of randomization to death due to any cause. When the patients who were lost to follow-up before death are recorded, the time of contact with the patient is the last recorded time. 1-5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Recruiting NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2